<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00189579</url>
  </required_header>
  <id_info>
    <org_study_id>TCHERCEPTIN1</org_study_id>
    <nct_id>NCT00189579</nct_id>
  </id_info>
  <brief_title>Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer</brief_title>
  <official_title>A Phase II Study Designed to Evaluate the Safety and Efficacy of the Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Early Relapse Patients (&lt; 6 Months) With Ovarian Cancer, Overexpressing HER2, Previously Treated With Carboplatin-Paclitaxel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether or not the addition of Herceptin may be of
      benefit to a standard regimen of carboplatin-paclitaxel.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <completion_date type="Actual">January 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older; patients with histologically proven diagnosis of ovarian cancer.

          -  Patients with metastatic disease and an overexpression of HER2 (as determined by
             immunochemistry)

          -  Patients who have progressed while receiving treatment, or within 6 months after
             completion of treatment. Patients must have received carboplatin and paclitaxel.

          -  Patients who have received at minimum one line of chemotherapy

          -  3 weeks minimum since last treatment with chemotherapy must have elapsed

          -  Patients must have at least 1 measurable lesion per Response Evaluation Criteria in
             Solid Tumors (RECIST) or an assessable cancer antigen (CA) 125 &gt; 1.25 x upper limit of
             normal (ULN)

          -  Patients must have ECOG of 2 or less

          -  Left ventricular ejection fraction (LVEF) of 50% or better

          -  Patients have given their signed and verbal consent

        Exclusion Criteria:

          -  Previous treatment with Herceptin or similar products affected growth factors (eg:
             Iressa)

          -  Another experimental treatment in the previous 30 days

          -  No overexpression of HER2 receptors

          -  Patients having received high-dose chemotherapy or stem-cell interventions

          -  Other cancers within the last 5 years

          -  Patients with dyspnea at rest or requiring oxygen therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Pujade-Lauraine, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Hotel-Dieu</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Hotel-Dieu</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>August 16, 2007</last_update_submitted>
  <last_update_submitted_qc>August 16, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2007</last_update_posted>
  <keyword>HERCEPTIN</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Relapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

